The Australian Fabry Disease Therapeutics Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Fabry Disease (also known as Anderson-Fabry Disease) is a rare genetic disorder which is caused by the deficiency of defective gene i.e., alpha-galactosidase-A gene (GLA gene) which leads to deficiency of an alpha-galactosidase enzyme. Alpha-galactosidase A (AGA) enzyme hydrolyses the terminal a -galactosyl moieties from glycolipids and glycoproteins. This disease is caused by an abnormal build-up of a specific fatty matter called globotriaosylceramide in multiple tissues of the body including eyes, skin, kidney, gastrointestinal system, brain, heart, and central nervous system.
People probably carry from 5 to 10 genes with mutations in each of their cells. It has been estimated that Fabry disease affects between 1:40,000 people, in males it is around 1:17,000. Fabry is seen across all ethnic groups. In a research, the average age of 44.5 years of Fabry affected patients has been reported while 81% of women and 61% of men has been found the classical Fabry disease.
Growing prevalence of Fabry Disease and its consequences on healthcare expenditure have augmented the demand for special treatments, positively impacting the Fabry Disease treatment market growth during the forecast period. The increasing focus on research activities and development of novel therapeutic drugs has uplifted the Fabry Disease therapeutics market value. Moreover, favourable government policies aiming at creating awareness pertaining to the Fabry disease treatment is leading to increased adoption of effective treatments of Fabry disease during the forecast period. However, there are several factors hindering the efficient and effective clinical trials of drug development of Fabry disease including low patient numbers, limited understanding of pathology and progression, and lack of established endpoints.
Fabry Disease Types:
Based on type, the Fabry Disease market can be segmented into type-1, type-2 and others. Among all, the maximum patients are identified being suffered from the type-2 Fabry disease, so the type-2 Fabry disease is anticipated to acquire a major market share during the forecast period.